Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 7/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | IDO1 | P14902 | 5/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30112774 | 0.84 | HSD17B10 (0.38) | TSHRHSD17B10POLBIDO1KDM4E | |
| SCHEMBL26924125 | 0.81 | TSHR (0.46) | TSHRHSD17B10POLBIDO1KDM4E | |
| SCHEMBL26924580 | 0.79 | TSHR (0.44) | TSHRHSD17B10POLBIDO1KDM4E | |
| SCHEMBL21462093 | 0.79 | ABCB11 (0.49) | HSD17B10POLBKDM4EALDH1A1HPGD | |
| SCHEMBL21480301 | 0.79 | ABCB11 (0.40) | HSD17B10KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL23159600 | 0.78 | TSHR (0.43) | TSHRHSD17B10POLBKDM4EALDH1A1 | |
| SCHEMBL21462094 | 0.77 | IDO1 (0.41) | TSHRHSD17B10POLBIDO1KDM4E | |
| SCHEMBL20745428 | 0.77 | TSHR (0.44) | TSHRHSD17B10POLBKDM4EALDH1A1 | |
| SCHEMBL23159590 | 0.76 | TSHR (0.42) | TSHRHSD17B10POLBKDM4EALDH1A1 | |
| SCHEMBL20745701 | 0.76 | TSHR (0.43) | TSHRHSD17B10POLBIDO1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739658-A1 | SYNTHESIS OF PYRUVATE KINASE ACTIVATORS | Agios Pharmaceuticals, Inc. (US) | 2026-05-13 | — | — | EP | disclosed |
| US-20250144093-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS | AGIOS PHARMACEUTICALS, INC. | 2025-05-08 | — | — | US | disclosed |
| WO-2025010390-A1 | SYNTHESIS OF PYRUVATE KINASE ACTIVATORS | AGIOS PHARMACEUTICALS, INC. (US) | 2025-01-09 | — | — | WO | disclosed |
| US-12133853-B2 | Pyruvate kinase activators for use in treating blood disorders | AGIOS PHARMACEUTICALS, INC. (US) | 2024-11-05 | — | — | US | disclosed |
| US-11957680-B2 | Pyruvate kinase activators for use in treating blood disorders | AGIOS PHARMACEUTICALS, INC. (US) | 2024-04-16 | — | — | US | disclosed |
| US-11872225-B2 | Pyruvate kinase modulators and use thereof | AGIOS PHARMACEUTICALS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| CN-117186119-A | Pyruvate kinase activators for the treatment of hematological disorders | 安吉奥斯医药品有限公司 | 2023-12-08 | — | — | CN | disclosed |
| EP-3668881-B1 | PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS | AGIOS PHARMACEUTICALS INC (US) | 2023-10-04 | — | — | EP | disclosed |
| CN-111032046-B | Pyruvate kinase modulators and uses thereof | 安吉奥斯医药品有限公司 | 2023-09-26 | — | — | CN | disclosed |
| CN-111032045-B | Pyruvate kinase activators for the treatment of hematological disorders | 安吉奥斯医药品有限公司 | 2023-08-15 | — | — | CN | disclosed |
| US-20200206225-A1 | PYRUVATE KINASE MODULATORS AND USE THEREOF | AGIOS PHARMACEUTICALS, INC. (US) | 2020-07-02 | — | — | US | disclosed |
| US-20200206225-A1 | PYRUVATE KINASE MODULATORS AND USE THEREOF | AGIOS PHARMACEUTICALS, INC. (US) | 2020-07-02 | — | — | US | disclosed |
| EP-3668512-A1 | PYRUVATE KINASE MODULATORS AND USE THEREOF | Agios Pharmaceuticals, Inc. (US) | 2020-06-24 | — | — | EP | disclosed |
| EP-3668513-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS | Agios Pharmaceuticals, Inc. (US) | 2020-06-24 | — | — | EP | disclosed |
| EP-3668881-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS | Agios Pharmaceuticals, Inc. (US) | 2020-06-24 | — | — | EP | disclosed |
| WO-2019196111-A1 | ANTI-TUMOR MULTIDRUG RESISTANCE OF HETEROARYL AMIDE COMPOUND, USE IN TREATMENT OF CANCERS AND PROTEIN-DRUG MOLECULAR COMPLEX | 上海交通大学医学院附属瑞金医院 | 2019-10-17 | — | — | WO | disclosed |
| CN-109748927-A | Heteroaryl amide compound, preparation method, Pharmaceutical composition and its application | 上海交通大学医学院附属瑞金医院 | 2019-05-14 | — | — | CN | disclosed |
| WO-2019035864-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS | AGIOS PHARMACEUTICALS, INC. (US) | 2019-02-21 | — | — | WO | disclosed |
| WO-2019035865-A1 | PYRUVATE KINASE MODULATORS AND USE THEREOF | AGIOS PHARMACEUTICALS INC. (US) | 2019-02-21 | — | — | WO | disclosed |
| WO-2019035863-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS | AGIOS PHARMACEUTICALS, INC. (US) | 2019-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11872225-B2 | Pyruvate kinase modulators and use thereof | PDK1, PDK2, PDK4 | TSHR 679/4885HSD17B10 767/4885POLB 3454/4885 |
| US-20200206225-A1 | PYRUVATE KINASE MODULATORS AND USE THEREOF | PDK1, PDK2, PDK4 | TSHR 679/4885HSD17B10 767/4885POLB 3454/4885 |
| US-11957680-B2 | Pyruvate kinase activators for use in treating blood disorders | PDK1, PDK2, PDK3 | TSHR 1925/4885HSD17B10 739/4885POLB 1880/4885 |
| US-12133853-B2 | Pyruvate kinase activators for use in treating blood disorders | PDK1, PDK2, PDK3 | TSHR 1762/4885HSD17B10 1064/4885POLB 1741/4885 |
| US-20250144093-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS | PDK1, PDK2, PDK3 | TSHR 1762/4885HSD17B10 1064/4885POLB 1741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.